TF and Kaposi's sarcoma: Our previous findings suggested SOX18 as an attractive therapeutic target for KS (Gramolelli et al., 2020; Tuohinto et al., 2023) and that this TF activity is directly modulated as part of R(+) -Propranolol off-target effects (Holm et al., 2025; Overman et al., 2019; Seebauer et al., 2022) in the context of infantile hemangioma.